ETSA winner Theranautilus heads to human trials; JSW One’s IPO plans
Bengaluru-based Theranautilus will begin human trials of its nanorobot dental technology in November-December, starting with 30 patients. Following initial trials, a 300-patient multicentric trial will aim for commercialisation within two years. Meanwhile, JSW One Platforms plans to file for a ₹3,000 crore IPO in the next few weeks, targeting a listing in FY28.